Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: Do stopped trials contribute to overall knowledge?

Italian Heart Journal

Volumn 1, Issue 12, 2000, Pages 810-820

  Marchioli, R ^a  

^a GISSI Prevenzione Coordinating Centre   (Italy)

Author keywords

Cholesterol; Clinical trials; Coronary heart disease

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; PATIENT COMPLIANCE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SKIN CANCER; STROKE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FOOD HABITS; HUMANS; ITALY; LIFE STYLE; MALE; MEDITERRANEAN REGION; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; TRIGLYCERIDES;

EID: 0034526070     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Statins do more than just lowering cholesterol
2. Cholesterol screening guidelines: Consensus, evidence, and departure from common sense
3. National cholesterol education program recommendations for cholesterol testing in young adults: A science-based approach
4. When to start cholesterol-lowering therapy in patients with coronary heart disease: A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
5. Management of hyperlipidaemia: Why, when and how to treat
6. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Il quadro di riferimento biochimico, farmacologico, epidemiologico del GISSI prevenzione
10. Il protocollo dello studio GISSI prevenzione: Studio di intervento preventivo sulle componenti aterosclerotica e trombotica del rischio post-infarto
11. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. GISSI-Prevenzione Investigators
12. Beneficial effects of statins. GISSI-Prevenzione Investigators
13. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
14. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction - ISIS-2
15. Accuracy of cholesterol measurements in Italian clinical laboratories. Joint project GISSI Prevention-Italian Society of Clinical Biochemistry. SIBioC Prevenzione Group
16. National cholesterol education program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary
17. Meta-analysis, clinical trials, and transferability of research results into practice: The case of cholesterol-lowering interventions in secondary prevention of coronary heart disease
18. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
19. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment
20. A European society of cardiology survey of secondary prevention of coronary heart disease: Principal results. European action on secondary prevention through intervention to reduce events
21. Statin trials and goals of cholesterol-lowering therapy
22. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
23. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
24. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
25. Protocol for a prospective overview of all current and planned randomized trials of cholesterol treatment regimens
26. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS